Testing effectiveness (Phase 2)Study completedNCT01654263
What this trial is testing
A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Who this might be right for
Pneumococcal Infection
National Institute of Allergy and Infectious Diseases (NIAID) 884